Anakinra Dosing for Post-Acute COVID Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet medical need for effective therapies to treat Post-Acute COVID Syndrome (PACS), characterized by debilitating symptoms such as fatigue, shortness of breath, and cognitive dysfunction, which affect a substantial number of COVID-19 survivors and impact daily functioning.
Innovation Solution
Anakinra, a recombinant interleukin-1 receptor antagonist, is administered at doses ranging from approximately 100 mg to 600 mg daily, typically via subcutaneous injection, to mitigate the inflammatory response associated with PACS, potentially alleviating symptoms and improving daily activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anakinra is administered to treat PACS, then inflammatory response is mitigated and symptoms are alleviated, but treatment complexity and dosing requirements increase
Solution Approach 1:
The patent specifies precise dosing parameters (100-600 mg daily) and administration timing (within 2 hours of each other) to optimize treatment effectiveness while managing complexity through standardized protocols
Solution Approach 2:
The treatment regimen requires daily administration of anakinra to maintain continuous suppression of the inflammatory response, ensuring sustained therapeutic effect throughout the treatment period
2Reliability
If higher doses of anakinra are used, then treatment effectiveness improves, but safety concerns and adverse effects increase
Solution Approach 1:
The patent establishes a dose range (100-600 mg) that balances therapeutic efficacy with safety, allowing flexible dosing based on patient response while maintaining safety margins through defined parameter limits
Solution Approach 2:
The treatment protocol incorporates monitoring of patient response and safety parameters, enabling adjustment of dosing based on individual patient feedback to optimize the balance between efficacy and adverse effects
3Reliability
If daily administration is required, then symptom relief is maintained, but patient burden and treatment time increase
Solution Approach 1:
Daily administration ensures continuous suppression of inflammation and consistent symptom control, preventing symptom flare-ups and maintaining therapeutic stability throughout the treatment period
Solution Approach 2:
The treatment utilizes periodic daily dosing cycles that maintain therapeutic levels through regular administration, with the option of extended treatment periods based on patient response to achieve long-term remission
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Anakinra treatment demonstrates improvements in lung function, cardiac function, and reduced cytokine production, leading to at least 20% improvement in restrictive lung disease and decreased hospitalization needs, while reducing symptoms like fatigue and shortness of breath.
Implementation Method 1
Anakinra is a recombinant form of a naturally occurring human interleukin-1 receptor antagonist (IL-1Ra) protein, functioning as a competitive inhibitor for receptor binding of IL-1
Implementation Method 2
Anakinra blocks the production of IL-6, a cytokine that is produced by PBMCs at significantly higher levels in patients recovering from COVID-19 pneumonia
Data Source
AI summary
The present invention relates to the human Interleukin 1 Receptor antagonist anakinra for use in the treatment of Post-Acute COVID Syndrome (PACS), wherein said treatment comprises administration of a dose of at least approximately 100 mg of anakinra to a patient in need thereof. Also, related treatment methods and pharmaceutical compositions for said use are disclosed.